THESEUS PHARMACEUTICALS, INC. Research and Development Expense
THESEUS PHARMACEUTICALS, INC. reported Research and Development Expense of $11.52 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-11-17
- THESEUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2023-09-30 was $11.52M, a 0.84% increase year-over-year.
- THESEUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2023-06-30 was $12.92M, a 75.91% increase year-over-year.
- THESEUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2023-03-31 was $12.40M, a 89.39% increase year-over-year.
- THESEUS PHARMACEUTICALS, INC. research and development expense for the quarter ending 2022-12-31 was $10.38M, a 106.75% increase year-over-year.
- THESEUS PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $35.70M, a 94.77% increase from fiscal 2021.
- THESEUS PHARMACEUTICALS, INC. research and development expense for fiscal 2021 was $18.33M, a 207.62% increase from fiscal 2020.
- THESEUS PHARMACEUTICALS, INC. research and development expense for fiscal 2020 was $5.96M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $11.52M 10-Q · filed 2023-11-17 | $24.44M derived: sum of 2 quarters · filed 2023-11-17 | $36.84M 10-Q · filed 2023-11-17 | $47.22M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-06-30 | $12.92M 10-Q · filed 2023-08-10 | $25.32M 10-Q · filed 2023-08-10 | $35.70M derived: sum of 3 quarters · filed 2023-08-10 | $47.13M derived: sum of 4 quarters · filed 2023-11-17 |
| 2023-03-31 | $12.40M 10-Q · filed 2023-05-11 | $22.78M derived: sum of 2 quarters · filed 2023-05-11 | $34.21M derived: sum of 3 quarters · filed 2023-11-17 | $41.55M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-12-31 | $10.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $21.81M derived: sum of 2 quarters · filed 2023-11-17 | $29.15M derived: sum of 3 quarters · filed 2023-11-17 | $35.70M 10-K · filed 2023-03-09 |
| 2022-09-30 | $11.42M 10-Q · filed 2023-11-17 | $18.77M derived: sum of 2 quarters · filed 2023-11-17 | $25.32M 10-Q · filed 2023-11-17 | $30.34M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | $7.34M 10-Q · filed 2023-08-10 | $13.89M 10-Q · filed 2023-08-10 | $18.91M derived: sum of 3 quarters · filed 2023-08-10 | $23.91M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $6.55M 10-Q · filed 2023-05-11 | $11.57M derived: sum of 2 quarters · filed 2023-05-11 | $16.57M derived: sum of 3 quarters · filed 2023-05-11 | $21.05M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $10.02M derived: sum of 2 quarters · filed 2023-03-09 | $14.50M derived: sum of 3 quarters · filed 2023-03-09 | $18.33M 10-K · filed 2023-03-09 |
| 2021-09-30 | $5.00M 10-Q · filed 2022-11-03 | $9.48M derived: sum of 2 quarters · filed 2022-11-03 | $13.31M 10-Q · filed 2022-11-03 | $15.79M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $4.49M 10-Q · filed 2022-08-11 | $8.31M 10-Q · filed 2022-08-11 | $10.80M derived: sum of 3 quarters · filed 2022-08-11 | $12.07M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $3.83M 10-Q · filed 2022-05-12 | $6.31M derived: sum of 2 quarters · filed 2022-05-12 | $7.59M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.76M derived: sum of 2 quarters · filed 2022-03-10 | $5.96M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $1.27M 10-Q · filed 2021-11-15 | $3.47M 10-Q · filed 2021-11-15 |